Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02445391 · OUTCOME

Proportion of Basal Subtype

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy · Source last updated 2026-07-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
Assessed at registration to step 0 (baseline)

What was measured

Proportion of basal subtype was calculated as number of patients who had basal subtype disease divided by all triple-negative breast cancers who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype results.

Analysis population: Analysis population was all patients who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype results. Before 6/22/2016, only basal subtype was randomized to arms A and B. After 6/22/2016, all eligible patients were randomized to arms B and C regardless of their intrinsic subtype. Proportion of basal subtype was calculated in the 396 patients who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype assay results at the final analysis time.

Groups in this outcome

All Patients Concurrently Randomized to Arms B and C

All patients who were randomized to arms B and C after 6/22/2016 (when arm C was open to accrual). Before 6/22/2016, only basal subtype was randomized to arms A and B. After 6/22/2016, all eligible patients were randomized regardless of their intrinsic subtype. Proportion of basal subtype was calculated in patients randomized after 6/22/2016.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients Concurrently Randomized to Arms B and C396

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients Concurrently Randomized to Arms B and C78Not reported7382Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        73
        upper Limit
        82
        value
        78
denoms
  1. counts
    1. group Id
      OG000
      value
      396
    units
    Participants
description
Proportion of basal subtype was calculated as number of patients who had basal subtype disease divided by all triple-negative breast cancers who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype results.
dispersion Type
95% Confidence Interval
groups
  1. description
    All patients who were randomized to arms B and C after 6/22/2016 (when arm C was open to accrual). Before 6/22/2016, only basal subtype was randomized to arms A and B. After 6/22/2016, all eligible patients were randomized regardless of their intrinsic subtype. Proportion of basal subtype was calculated in patients randomized after 6/22/2016.
    id
    OG000
    title
    All Patients Concurrently Randomized to Arms B and C
param Type
NUMBER
population Description
Analysis population was all patients who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype results. Before 6/22/2016, only basal subtype was randomized to arms A and B. After 6/22/2016, all eligible patients were randomized to arms B and C regardless of their intrinsic subtype. Proportion of basal subtype was calculated in the 396 patients who were randomized to arms B and C after 6/22/2016 and had intrinsic subtype assay results at the final analysis time.
reporting Status
POSTED
time Frame
Assessed at registration to step 0 (baseline)
title
Proportion of Basal Subtype
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice